高血脂症是現代社會常見的代謝性疾病，是導致冠狀動脈疾病以及腦血管疾病的重要因素之一。本研究選取經研究指出具有降血脂作用之中藥處方--「六味地黃丸」和「降脂方」，進行高血脂症之治療，以評估兩項處方調降血脂之作用，作為中醫師臨床治療高血脂症病患之實證依據。本研究為一開放、隨機、平行對照試驗，於門診徵求40位高血脂症病人，經簽署試驗知情同意書，隨機分配到六味地黃丸組或降脂方組進行8週中藥處方治療。經過8 週的治療，六味地黃丸治療組，低密度脂蛋白膽固醇(LDL-C)與三酸甘油脂(TG)呈現下降之趨勢，但未達統計顯著意義。降脂方治療組，三酸甘油脂(TG)呈現下降之趨勢，而低密度脂蛋白膽固醇(LDL-C)卻有些微上升的改變，但皆未達顯著意義。此外，不論六味地黃丸組或是降脂方組皆呈現顯著的體重以及BMI 下降的情形，P 值<0.05。服藥前後檢視病患之肝、腎功能，無明顯變化，確認藥物對於肝、腎功能之安全性。本研究顯示六味地黃丸具有降低高血脂症病患血中低密度脂蛋白膽固醇(LDL-C)、三酸甘油脂(TG)濃度的潛力；而降脂方調降三酸甘油脂的能力優於調降低密度脂蛋白膽固醇(LDL-C)的能力。期待進一步之基礎與臨床的研究，將有助於驗證中藥處方對於高血脂症的療效，並加以突破，作為中醫藥實證醫學與推展中醫藥政策之依據。

Hyperlipidemia is a common metabolic disease, which is the important factor of coronary artery disease as well as cerebrovascular disease. This study selects 2 documented effective Chinese medicine formulas for hyperlipidemia-- “Liuwei Dihuang Wan” and “Lipid-Lowering-Tea”. The
aim of this study is to evaluate the clinical efficacy on cholesterol-lowering effect of the two prescriptions. This study is an open,
randomized, parallel clinical trial. We screened and rerolled 40
participants with hyperlipidemia. After signature of the informed consent form, these participants were randomized assigned to 2 different groups for hyperlipidemia treatment for 8 weeks. “Liuwei Dihuang Wan” group showed the potential to reduce lower-density lipoprotein cholesterol (LDL-C)and triglyceride (TG), but all have not reached the remarkable significance. “Lipid-Lowering-Tea”group showed the tendency to level down TG, but not LDL-C, and all have not reached the remarkable significance. The above 2 prescriptions showed the efficacy to lower body weight and
BMI, and statistics showed remarkable significance, p-value < 0.05. Besides, after the 8 weeks treatment, all the patients’ liver and renal function is intact, which showed the safety of the 2 prescriptions. This study showed the tendency of the lipid-lowering effect of the “Liuwei Dihuang Wan” and “Lipid-Lowering-Tea”. We expect the further randomized, double-blinded, study to evaluate the efficacy of Chinese Medicine.